Flot.bio hat dies direkt geteilt
New episode: here’s my conversation with Harpreet Singh of Immatics, one of the 15 most valuable 🇪🇺 biotechs. “We think that TCRs are key to making solid cancers accessible to Immunotherapies because TCRs can tap into the intra-cellular target space.” We also talked about Cell Therapy at large and why there is scepticism at the moment. “Well, it matters so much whether you get it right. This is true for every kind of drug, but for cell therapy, you have a relatively high cost of goods, so you have to give something back in return that is so mind-blowing for physicians, patients, for payers.” We finished on the combination with mRNA therapeutics and his upbringing in a Sikh family in Germany. You can now watch and listen to the full episode for free on YouTube, Spotify or Apple (link in the comments). What do you think? 🤔 P.S. Have you noticed the new background music to celebrate episode 20?